Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension
- 25 July 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (15) , 6622-6637
Abstract
Phosphodiesterase 5 (PDE5) inhibitors have been used as clinical agents to treat erectile dysfunction and pulmonary arterial hypertension (PAH). Herein, we detail the discovery of a novel series of chromeno[2,3-c]pyrrol-9(2H)-one derivatives as selective and orally bioavailable inhibitors against phosphodiesterase 5. Medicinal chemistry optimization resulted in 2, which exhibits a desirable inhibitory potency of 5.6 nM with remarkable selectivity as well as excellent pharmacokinetic properties and an oral bioavailability of 63.4%. In addition, oral administration of 2 at a dose of 5.0 mg/kg caused better pharmacodynamics effects on both mPAP (mean pulmonary artery pressure) and RVHI (index of right ventricle hypertrophy) than sildenafil citrate at a dose of 10.0 mg/kg. These activities along with its reasonable druglike properties, such as human liver microsomal stability, cytochrome inhibition, hERG inhibition, and pharmacological safety, indicate that 2 is a potential candidate for the treatment of PAH.Keywords
Funding Information
- National Natural Science Foundation of China (21572279, 81373258, 81522041, 81602968)
- Natural Science Foundation of Guangdong Province (2014A020210009, 2016A030310144)
- Guangdong Province
This publication has 51 references indexed in Scilit:
- Treating pulmonary arterial hypertension: current treatments and future prospectsTherapeutic Advances in Chronic Disease, 2011
- ACCF/AHA 2009 Expert Consensus Document on Pulmonary HypertensionCirculation, 2009
- Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial HypertensionCirculation, 2008
- A USA-based registry for pulmonary arterial hypertension: 1982–2006European Respiratory Journal, 2007
- Medical Therapy for Pulmonary Arterial HypertensionChest, 2007
- Right Ventricular Function and FailureCirculation, 2006
- Tissue expression, distribution, and regulation of PDE5International Journal Of Impotence Research, 2004
- Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitroThe American Journal of Cardiology, 1999
- [65] Purification of cGMP-binding protein phosphodiesterase from rat lung1988
- [64] Platelet cGMP-binding phosphodiesterase1988